Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHOK PATEL

NPI
1093809576
CMS profile
276954
Location
TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,320.42

66 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHOK PATEL

NPI 1093809576 · CMS profile ID 276954

TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093809576?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093809576?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093809576?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1093809576?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

66 matching records · $2,320.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 66 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 66.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $5.8712/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925209 CMS
Allergan Inc. $10.0012/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925199 CMS
Allergan Inc. $69.6012/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925201 CMS
Allergan Inc. $17.3612/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925203 CMS
Allergan Inc. $1,625.0012/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925207 CMS
Teva Pharmaceuticals USA, Inc. $13.8712/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697829883 CMS
Allergan Inc. $7.4412/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925195 CMS
Allergan Inc. $2.8511/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925192 CMS
Neurocrine Biosciences, Inc. $11.7211/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693155315 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.3311/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682107259 CMS
Otsuka America Pharmaceutical, Inc. $13.4711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687454663 CMS
Jazz Pharmaceuticals Inc. $12.5411/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684537179 CMS
Allergan Inc. $6.1510/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925189 CMS
Teva Pharmaceuticals USA, Inc. $12.9910/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697779641 CMS
Vanda Pharmaceuticals Inc. $13.2810/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697667459 CMS
Jazz Pharmaceuticals Inc. $12.5410/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684537129 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.0910/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681733549 CMS
Allergan Inc. $1.5510/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925187 CMS
Avanir Pharmaceuticals, Inc. $11.2310/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653607917 CMS
Shire North American Group Inc $14.8610/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637892661 CMS
Allergan Inc. $1.9810/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925179 CMS
Allergan Inc. $1.9610/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925183 CMS
Vanda Pharmaceuticals Inc. $13.7710/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697667457 CMS
Neurocrine Biosciences, Inc. $20.9409/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693155313 CMS
Allergan Inc. $4.4309/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925173 CMS
Allergan Inc. $2.1309/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925177 CMS
Avanir Pharmaceuticals, Inc. $13.6209/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653607923 CMS
Teva Pharmaceuticals USA, Inc. $11.3309/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697800623 CMS
Vanda Pharmaceuticals Inc. $14.8109/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697667455 CMS
Allergan Inc. $6.2708/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925171 CMS
ACADIA Pharmaceuticals Inc $14.3308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700017767 CMS
Allergan Inc. $3.4908/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925167 CMS
Avanir Pharmaceuticals, Inc. $18.6808/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653607921 CMS
Shire North American Group Inc $14.5308/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637892659 CMS
Allergan Inc. $14.1707/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925165 CMS
Allergan Inc. $2.6307/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925161 CMS
Avanir Pharmaceuticals, Inc. $11.0207/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653607925 CMS
Vanda Pharmaceuticals Inc. $11.3507/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697667453 CMS
Lundbeck LLC $11.5007/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684327663 CMS
Allergan Inc. $2.9007/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925158 CMS
Allergan Inc. $2.9605/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925153 CMS
Avanir Pharmaceuticals, Inc. $12.5105/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653607919 CMS
Allergan Inc. $1.7305/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925149 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.0305/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682101085 CMS
ACADIA Pharmaceuticals Inc $14.1704/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700017765 CMS
Vanda Pharmaceuticals Inc. $12.0604/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697667451 CMS
Janssen Pharmaceuticals, Inc $14.0604/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659165485 CMS
Avanir Pharmaceuticals, Inc. $13.5204/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653607915 CMS
Neurocrine Biosciences, Inc. $12.8204/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693155311 CMS
Allergan Inc. $10.8504/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925147 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.42 66
PY2020 $2,969.84 33
PY2021 $7,553.27 35
PY2022 $6,054.38 18
PY2023 $14,560.76 55
PY2024 $22,723.92 31
PY2025 $6,910.62 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,752.51 11
PY2025 Principal investigator $1,229,009.00 130
PY2024 Principal investigator $3,194,861.98 28
PY2023 Recipient $355.00 1
PY2023 Principal investigator $1,914,939.19 59
PY2022 Recipient $1,248.00 4
PY2022 Principal investigator $1,105,512.02 75
PY2021 Recipient $13,374.00 3
PY2021 Principal investigator $1,695,784.21 81
PY2020 Recipient $6,288.97 21
PY2020 Principal investigator $1,118,610.73 104
PY2019 Recipient $18,854.85 12
PY2019 Principal investigator $1,138,230.38 171

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

183 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $110.00 12/31/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670119049
Principal investigator 1 Allergan Inc. $300.46 12/31/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670119225
Principal investigator 1 Allergan Inc. $20,249.37 12/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670122783
Principal investigator 1 Allergan Inc. $573.50 12/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670123135
Principal investigator 1 Allergan Inc. $12,097.80 12/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670123536
Principal investigator 1 Allergan Inc. $14,510.59 12/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670127135
Principal investigator 1 Eisai Inc. $1,186.00 12/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513849
Principal investigator 1 Eisai Inc. $1,186.00 12/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513851
Principal investigator 1 Eisai Inc. $1,186.00 12/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513853
Principal investigator 1 Amgen Inc. $7,500.00 12/21/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 675783399
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670114505
Principal investigator 1 Allergan Inc. $2,000.00 12/17/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670115201
Principal investigator 1 Allergan Inc. $3,800.00 12/16/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670112135
Principal investigator 1 Allergan Inc. $6,868.50 12/16/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670112691
Principal investigator 1 Allergan Inc. $3,958.65 12/13/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670109887
Principal investigator 1 Allergan Inc. $18,323.60 12/13/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670110499
Principal investigator 1 Allergan Inc. $2,711.60 12/05/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670106679
Principal investigator 1 Allergan Inc. $2,000.00 11/26/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670103523
Principal investigator 1 Allergan Inc. $10,000.00 11/26/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670104133
Principal investigator 1 Eisai Inc. $2,560.00 11/26/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513871
Principal investigator 1 Eisai Inc. $2,560.00 11/26/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513873
Principal investigator 1 Eisai Inc. $2,560.00 11/26/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513875
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $6,000.00 11/25/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 696055127
Principal investigator 1 Allergan Inc. $3,372.50 11/22/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670103306
Principal investigator 1 Avanir Pharmaceuticals, Inc. $6,880.50 11/21/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-303 No dispute reported 06/30/2026 656016961
Principal investigator 1 Allergan Inc. $1,476.30 11/13/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670096471
Principal investigator 1 Allergan Inc. $14,763.95 11/13/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096683
Principal investigator 1 Allergan Inc. $3,495.05 11/13/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670097065
Principal investigator 1 Allergan Inc. $86.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095363
Principal investigator 1 Allergan Inc. $327.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095819
Principal investigator 1 ACADIA Pharmaceuticals Inc $279.46 11/06/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699990253
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,500.00 11/06/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
ACP-103-056 No dispute reported 06/30/2026 699990271
Principal investigator 1 Allergan Inc. $11,067.50 11/05/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670094609
Principal investigator 1 Allergan Inc. $14,739.25 11/05/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670094719
Principal investigator 1 Allergan Inc. $900.00 11/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670093773
Principal investigator 1 Allergan Inc. $5,500.00 10/31/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670092553
Principal investigator 1 Allergan Inc. $666.24 10/31/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670093067
Principal investigator 1 Eisai Inc. $3,854.00 10/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513859
Principal investigator 1 Eisai Inc. $1,600.00 10/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513861
Principal investigator 1 Eisai Inc. $3,854.00 10/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513863
Principal investigator 1 Eisai Inc. $1,600.00 10/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513865
Principal investigator 1 Eisai Inc. $3,854.00 10/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513867
Principal investigator 1 Eisai Inc. $1,600.00 10/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513869
Principal investigator 1 Allergan Inc. $2,700.00 10/24/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670091615
Principal investigator 1 Eisai Inc. $2,800.00 10/24/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513857
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670088457
Principal investigator 1 Allergan Inc. $1,500.00 10/22/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670089007
Principal investigator 1 Allergan Inc. $1,500.00 10/22/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670089011
Principal investigator 1 Allergan Inc. $1,500.00 10/22/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670089625
Principal investigator 1 Allergan Inc. $3,018.15 10/22/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670089877
Principal investigator 1 Amgen Inc. $9,669.84 10/21/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 675783397
Principal investigator 1 Allergan Inc. $10,866.10 10/15/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670085547
Principal investigator 1 Allergan Inc. $4,690.00 10/08/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670083469
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $217.92 10/08/2019 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 696051309
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 10/08/2019 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 696051311
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 10/08/2019 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 696051315
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $718.84 10/08/2019 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 696051317
Principal investigator 1 ACADIA Pharmaceuticals Inc $10,683.30 10/07/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699990067
Principal investigator 1 Eisai Inc. $2,275.00 10/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513819
Principal investigator 1 Eisai Inc. $1,186.00 10/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513821
Principal investigator 1 Eisai Inc. $2,275.00 10/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513823
Principal investigator 1 Eisai Inc. $4,059.00 10/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513825
Principal investigator 1 Eisai Inc. $1,600.00 10/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513827
Principal investigator 1 ACADIA Pharmaceuticals Inc $8,500.00 09/23/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
ACP-103-056 No dispute reported 06/30/2026 699989891
Principal investigator 1 Eli Lilly and Company $31,795.00 09/23/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY No dispute reported 06/30/2026 654289529
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,000.00 09/20/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989855
Principal investigator 1 Allergan Inc. $17,588.30 09/20/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670078881
Principal investigator 1 Allergan Inc. $2,500.00 09/20/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670079045
Principal investigator 1 Allergan Inc. $9,000.00 09/20/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670079053
Principal investigator 1 Allergan Inc. $17,068.65 09/18/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670076657
Principal investigator 1 Allergan Inc. $5,510.00 09/13/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670075179
Recipient ACADIA Pharmaceuticals Inc $69.60 09/11/2019 Covered Recipient Physician ACP-103-056 No dispute reported 06/30/2026 699987393
Recipient ACADIA Pharmaceuticals Inc $75.00 09/11/2019 Covered Recipient Physician ACP-103-056 No dispute reported 06/30/2026 699987395
Principal investigator 1 Allergan Inc. $86.00 09/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670073095
Principal investigator 1 ACADIA Pharmaceuticals Inc $19,025.71 09/04/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989783
Principal investigator 1 Allergan Inc. $304.00 09/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670071665
Principal investigator 1 Allergan Inc. $660.00 08/27/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670069909
Principal investigator 1 Allergan Inc. $18,898.35 08/23/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670068624
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,366.65 08/19/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989701
Principal investigator 1 Allergan Inc. $20,639.70 08/16/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670067101
Principal investigator 1 Allergan Inc. $18,995.00 08/15/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670065673
Principal investigator 1 Allergan Inc. $9,705.05 08/15/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670065695
Principal investigator 1 Eisai Inc. $4,059.00 08/15/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513829
Principal investigator 1 Eisai Inc. $1,600.00 08/15/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513831
Principal investigator 1 Eisai Inc. $3,802.00 08/15/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513833
Principal investigator 1 Eisai Inc. $2,175.00 08/15/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513839
Principal investigator 1 Eisai Inc. $380.20 08/15/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513855
Principal investigator 1 Allergan Inc. $14,185.40 08/14/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670065329
Recipient ACADIA Pharmaceuticals Inc $172.46 08/09/2019 Covered Recipient Physician ACP-103-056 No dispute reported 06/30/2026 699987389
Recipient ACADIA Pharmaceuticals Inc $670.26 08/09/2019 Covered Recipient Physician ACP-103-056 No dispute reported 06/30/2026 699987391
Recipient ACADIA Pharmaceuticals Inc $186.26 08/08/2019 Covered Recipient Physician ACP-103-056 No dispute reported 06/30/2026 699987385
Recipient ACADIA Pharmaceuticals Inc $109.68 08/08/2019 Covered Recipient Physician ACP-103-056 No dispute reported 06/30/2026 699987387
Principal investigator 1 ACADIA Pharmaceuticals Inc $22,836.21 08/07/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989639
Principal investigator 1 Allergan Inc. $10,157.40 07/30/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670061975
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $1,525.00 07/26/2019 Non-covered Recipient Entity
CLINICAL TRIAL ADVANTAGE LLC
PROTOCOL 331-201-00080 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE ACUTE TREATMENT OF MANIC EPISODES, WITH OR WITHOUT MIXED FEATURES, ASSOCIATED WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 696054765
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,000.00 07/19/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989559
Principal investigator 1 Eli Lilly and Company $1,290.00 07/17/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654287929
Principal investigator 1 Allergan Inc. $16,328.60 07/16/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057397
Principal investigator 1 Allergan Inc. $28,553.20 07/15/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670056959
Principal investigator 1 ACADIA Pharmaceuticals Inc $11,699.78 07/10/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-033 No dispute reported 06/30/2026 699989549
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,937.71 07/05/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989459
Principal investigator 1 Allergan Inc. $18,580.10 07/02/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670054791
Principal investigator 1 Allergan Inc. $5,907.10 06/25/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670053027
Principal investigator 1 Allergan Inc. $9,000.00 06/20/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670052521
Principal investigator 1 Avanir Pharmaceuticals, Inc. $7,121.00 06/20/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-303 No dispute reported 06/30/2026 656016959
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,184.20 06/06/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989303
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $29,178.74 06/06/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A 12-WEEK, MULTICENTER, ACTIVE-TREATMENT EXTENSION TRIAL TO EVAULATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE No dispute reported 06/30/2026 696054595
Recipient Allergan Inc. $2.83 05/28/2019 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670008335
Principal investigator 1 Allergan Inc. $15,364.35 05/28/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670048537
Principal investigator 1 Allergan Inc. $955.00 05/28/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670048918
Principal investigator 1 Eisai Inc. $250.00 05/23/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513835
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,786.85 05/21/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989157
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,000.00 05/21/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699989159
Principal investigator 1 Allergan Inc. $2,500.00 05/21/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670047071
Principal investigator 1 Eisai Inc. $250.00 05/21/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513837
Principal investigator 1 Eli Lilly and Company $1,720.00 05/20/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA No dispute reported 06/30/2026 654289047
Principal investigator 1 ACADIA Pharmaceuticals Inc $60.75 05/17/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
ACP-103-033 No dispute reported 06/30/2026 699989153
Principal investigator 1 Allergan Inc. $2,000.00 05/17/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670046559
Principal investigator 1 Allergan Inc. $10,000.00 05/17/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670046565
Principal investigator 1 Avanir Pharmaceuticals, Inc. $33.01 05/16/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-301 No dispute reported 06/30/2026 656016957
Principal investigator 1 Eisai Inc. $4,059.00 05/07/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513841
Principal investigator 1 Eisai Inc. $1,600.00 05/07/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513843
Principal investigator 1 Eisai Inc. $1,186.00 05/07/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513845
Principal investigator 1 ACADIA Pharmaceuticals Inc $200.00 05/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
ACP-103-033 No dispute reported 06/30/2026 699989067
Principal investigator 1 ACADIA Pharmaceuticals Inc $200.00 05/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
ACP-103-033 No dispute reported 06/30/2026 699989069
Principal investigator 1 ACADIA Pharmaceuticals Inc $200.00 05/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
ACP-103-033 No dispute reported 06/30/2026 699989071
Principal investigator 1 ACADIA Pharmaceuticals Inc $200.00 05/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
ACP-103-033 No dispute reported 06/30/2026 699989073
Principal investigator 1 ACADIA Pharmaceuticals Inc $300.00 05/01/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
ACP-103-033 No dispute reported 06/30/2026 699989075
Principal investigator 1 Allergan Inc. $16,666.80 04/25/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670041235
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,500.00 04/25/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-301 No dispute reported 06/30/2026 656016955
Principal investigator 1 Allergan Inc. $8,000.00 04/18/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670038177
Principal investigator 1 Avanir Pharmaceuticals, Inc. $3,942.00 04/18/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-301 No dispute reported 06/30/2026 656016953
Principal investigator 1 Avanir Pharmaceuticals, Inc. $3,898.50 04/11/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
17-AVP-825-301 No dispute reported 06/30/2026 656016949
Principal investigator 1 Avanir Pharmaceuticals, Inc. $9,699.00 04/11/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-301 No dispute reported 06/30/2026 656016951
Principal investigator 1 Eli Lilly and Company $53.19 04/10/2019 Non-covered Recipient Entity
BARRY J REINER MD LLC
EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY No dispute reported 06/30/2026 654288381
Principal investigator 1 Allergan Inc. $19,847.40 04/09/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670036267
Principal investigator 1 ACADIA Pharmaceuticals Inc $10,154.98 04/05/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699988831
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,116.48 04/03/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
ACP-103-033 No dispute reported 06/30/2026 699988823
Principal investigator 1 Eisai Inc. $2,175.00 04/02/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513847
Principal investigator 1 Allergan Inc. $25,953.05 03/26/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670033704
Principal investigator 1 Eli Lilly and Company $963.52 03/26/2019 Non-covered Recipient Entity
MAYO CLINIC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 654291073
Principal investigator 1 Allergan Inc. $15,160.00 03/19/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670031371
Principal investigator 1 Allergan Inc. $722.00 03/14/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670030445
Principal investigator 1 Eisai Inc. $1,535.00 03/12/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513807
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513809
Principal investigator 1 Eisai Inc. $2,388.00 03/12/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513811
Principal investigator 1 Eisai Inc. $1,903.00 03/12/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513813
Principal investigator 1 Eisai Inc. $2,848.00 03/12/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513815
Principal investigator 1 Eisai Inc. $3,871.00 03/12/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513817
Principal investigator 1 Eli Lilly and Company $2,694.43 03/08/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY No dispute reported 06/30/2026 654288611
Principal investigator 1 Allergan Inc. $500.00 03/05/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670029041
Principal investigator 1 Allergan Inc. $13,970.70 02/28/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028073
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,354.75 02/27/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-033 No dispute reported 06/30/2026 699988583
Principal investigator 1 Allergan Inc. $4,607.50 02/21/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670026219
Principal investigator 1 ACADIA Pharmaceuticals Inc $285.53 02/13/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-033 No dispute reported 06/30/2026 699988535
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,259.98 02/06/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699988417
Principal investigator 1 Allergan Inc. $16,075.90 02/05/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021543
Principal investigator 1 Eli Lilly and Company $62,653.00 02/05/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 654288945
Principal investigator 1 Eli Lilly and Company $405.75 01/31/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 654288477
Principal investigator 1 ACADIA Pharmaceuticals Inc $100.00 01/30/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-033 No dispute reported 06/30/2026 699988343
Principal investigator 1 ACADIA Pharmaceuticals Inc $6,000.00 01/30/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-033 No dispute reported 06/30/2026 699988345
Principal investigator 1 Avanir Pharmaceuticals, Inc. $6,277.50 01/24/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-301 No dispute reported 06/30/2026 656016947
Principal investigator 1 Eisai Inc. $1,535.00 01/24/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513795
Principal investigator 1 Eisai Inc. $1,196.00 01/24/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513797
Principal investigator 1 Eisai Inc. $2,003.00 01/24/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513799
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513801
Principal investigator 1 Eisai Inc. $2,175.00 01/24/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513803
Principal investigator 1 Eisai Inc. $1,186.00 01/24/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513805
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,212.00 01/23/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699988197
Principal investigator 1 ACADIA Pharmaceuticals Inc $14,964.22 01/23/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 699988199
Principal investigator 1 Allergan Inc. $8,968.00 01/17/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670017365
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $72,076.05 01/17/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE OPC34712 IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 696053071
Principal investigator 1 Allergan Inc. $3,300.00 01/10/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670016059
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,391.18 01/09/2019 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-033 No dispute reported 06/30/2026 699988149
Principal investigator 1 Allergan Inc. $9,000.00 01/08/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670015527
Recipient Eli Lilly and Company $16,532.00 01/08/2019 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 654281153
Principal investigator 1 Allergan Inc. $36,712.75 01/03/2019 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670014193
Principal investigator 1 Eisai Inc. $1,535.00 01/03/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513783
Principal investigator 1 Eisai Inc. $1,196.00 01/03/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513785
Principal investigator 1 Eisai Inc. $2,003.00 01/03/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513787
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513789
Principal investigator 1 Eisai Inc. $1,186.00 01/03/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513791
Principal investigator 1 Eisai Inc. $3,871.00 01/03/2019 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702513793